Stifel Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $28.00 price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
